BioWorld

Dec. 14, 2005

View Archived Issues

Vertex, GSK In Potential $405M VX-409 Preclinical Collaboration

Partnering a promising preclinical pain product, Vertex Pharmaceuticals Inc. granted GlaxoSmithKline plc worldwide development and commercialization rights in a deal worth up to $405 million plus royalties. (BioWorld Today) Read More

Insmed's iPlex: Second Orphan Drug Approved In Short Stature

Read More

Missed Phase II Velafermin Endpoint Drops CuraGen

Read More

Halozyme's Stock Sale Raising $16.1M After Nod For Hylenex

Read More

Other News To Note

Read More

ASH Roundup

Read More